Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Casi Phrmactcls Inc (CASI)

Casi Phrmactcls Inc (CASI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,157
  • Shares Outstanding, K 139,797
  • Annual Sales, $ 15,140 K
  • Annual Income, $ -48,290 K
  • 60-Month Beta 0.34
  • Price/Sales 3.15
  • Price/Cash Flow N/A
  • Price/Book 1.01
Trade CASI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings N/A on 11/12/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +58.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5803 +1.48%
on 01/27/22
0.8700 -32.31%
on 12/28/21
-0.2332 (-28.37%)
since 12/27/21
3-Month
0.5803 +1.48%
on 01/27/22
1.1700 -49.67%
on 11/03/21
-0.4611 (-43.91%)
since 10/27/21
52-Week
0.5803 +1.48%
on 01/27/22
3.6800 -84.00%
on 02/03/21
-2.9711 (-83.46%)
since 01/27/21

Most Recent Stories

More News
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

CASI : 0.5875 (-5.24%)
Pre-Market Brief: Stocks See Support from Dovish Chinese Policy News

Morning Markets Dec S&P 500 futures this morning are up by +0.21%. Stocks are seeing support from a rally in Chinese stocks today on signs that China’s central bank may soon ease monetary policy. In...

MRNA : 148.62 (-4.09%)
VG : 20.82 (+0.05%)
GFS : 44.68 (-6.13%)
CASI : 0.5875 (-5.24%)
ASTR : 4.33 (-6.88%)
ATVI : 78.91 (+0.17%)
PGNY : 36.81 (-0.89%)
AUPH : 14.60 (-5.50%)
CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CASI : 0.5875 (-5.24%)
CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 0.5875 (-5.24%)
CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy?

CASI Pharma (CASI) has been struggling lately, but the selling pressure may be coming to an end soon.

CASI : 0.5875 (-5.24%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.4516 (-5.92%)
ABVC : 2.50 (-0.79%)
TRIL : 18.44 (+2.62%)
CASI : 0.5875 (-5.24%)
SESN : 0.6856 (-4.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

3rd Resistance Point 0.6862
2nd Resistance Point 0.6681
1st Resistance Point 0.6422
Last Price 0.5875
1st Support Level 0.5982
2nd Support Level 0.5801
3rd Support Level 0.5542

See More

52-Week High 3.6800
Fibonacci 61.8% 2.4959
Fibonacci 50% 2.1302
Fibonacci 38.2% 1.7644
Last Price 0.5875
52-Week Low 0.5803

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar